WO2005081619A3 - Compounds and methods for increasing neurogenesis - Google Patents

Compounds and methods for increasing neurogenesis Download PDF

Info

Publication number
WO2005081619A3
WO2005081619A3 PCT/IB2004/004451 IB2004004451W WO2005081619A3 WO 2005081619 A3 WO2005081619 A3 WO 2005081619A3 IB 2004004451 W IB2004004451 W IB 2004004451W WO 2005081619 A3 WO2005081619 A3 WO 2005081619A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compounds
neurogenesis
increasing neurogenesis
modulating agents
Prior art date
Application number
PCT/IB2004/004451
Other languages
French (fr)
Other versions
WO2005081619A2 (en
Inventor
Goran Bertilsson
Rikard Erlandsson
Jonas Frisen
Anders Haegestrand
Jessica Heidrich
Nina Hellstrom
Johan Haggblad
Katarina Jansson
Jarkko Kortesmaa
Per Lindquist
Hanna Lundh
Jacqueline Mcguire
Alex Mercer
Karl Nyberg
Amina Ossoinak
Cesare Patrone
Harriet Ronnholm
Lilian Wirkstrom
Olof Zachrisson
Original Assignee
Neuronova Ab
Goran Bertilsson
Rikard Erlandsson
Jonas Frisen
Anders Haegestrand
Jessica Heidrich
Nina Hellstrom
Johan Haggblad
Katarina Jansson
Jarkko Kortesmaa
Per Lindquist
Hanna Lundh
Jacqueline Mcguire
Alex Mercer
Karl Nyberg
Amina Ossoinak
Cesare Patrone
Harriet Ronnholm
Lilian Wirkstrom
Olof Zachrisson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2003/005311 external-priority patent/WO2004045592A2/en
Priority claimed from US10/850,055 external-priority patent/US6969702B2/en
Application filed by Neuronova Ab, Goran Bertilsson, Rikard Erlandsson, Jonas Frisen, Anders Haegestrand, Jessica Heidrich, Nina Hellstrom, Johan Haggblad, Katarina Jansson, Jarkko Kortesmaa, Per Lindquist, Hanna Lundh, Jacqueline Mcguire, Alex Mercer, Karl Nyberg, Amina Ossoinak, Cesare Patrone, Harriet Ronnholm, Lilian Wirkstrom, Olof Zachrisson filed Critical Neuronova Ab
Priority to CA2546843A priority Critical patent/CA2546843C/en
Priority to EP04821493A priority patent/EP1750752A2/en
Publication of WO2005081619A2 publication Critical patent/WO2005081619A2/en
Publication of WO2005081619A3 publication Critical patent/WO2005081619A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention is directed to methods of promoting neurogenesis by contacting neuronal tissue with neurogenesis modulating agents. Novel methods for treating neurological disorders using neurogenesis modulating agents are disclosed.
PCT/IB2004/004451 2003-11-20 2004-11-19 Compounds and methods for increasing neurogenesis WO2005081619A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA2546843A CA2546843C (en) 2003-11-20 2004-11-19 Compounds and methods for increasing neurogenesis
EP04821493A EP1750752A2 (en) 2003-11-20 2004-11-19 Compounds and methods for increasing neurogenesis

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
PCT/IB2003/005311 WO2004045592A2 (en) 2002-11-20 2003-11-20 Compounds and methods for increasing neurogenesis
IBPCT/IB03/05311 2003-11-20
US10/718,071 2003-11-20
US10/718,071 US20050009847A1 (en) 2002-11-20 2003-11-20 Compounds and methods for increasing neurogenesis
US10/850,055 US6969702B2 (en) 2002-11-20 2004-05-19 Compounds and methods for increasing neurogenesis
US10/850,055 2004-05-19

Publications (2)

Publication Number Publication Date
WO2005081619A2 WO2005081619A2 (en) 2005-09-09
WO2005081619A3 true WO2005081619A3 (en) 2007-04-19

Family

ID=34915966

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/004451 WO2005081619A2 (en) 2003-11-20 2004-11-19 Compounds and methods for increasing neurogenesis

Country Status (3)

Country Link
EP (1) EP1750752A2 (en)
CA (1) CA2546843C (en)
WO (1) WO2005081619A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2647568A1 (en) * 2006-03-31 2007-10-11 Amylin Pharmaceuticals, Inc. Amylin and amylin agonists for treating psychiatric diseases and disorders
CA2672524C (en) * 2006-12-14 2016-08-23 Neuronova Ab Treatment of disease or injury of the nervous system using agents that decrease the activity of the melanocortin 4 receptor
CA2699087A1 (en) * 2007-09-11 2009-04-16 Dorian Bevec Use of a peptide as a therapeutic agent
CA2698690A1 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Thyrotropin releasing hormone for therapeutic applications
WO2009033809A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US20110263642A1 (en) * 2008-08-26 2011-10-27 Fibrogen, Inc. Methods for treatment of multiple sclerosis
CN102924587B (en) * 2011-08-11 2016-08-24 中肽生化有限公司 Long-acting salmon calcitonin analogues and its production and use
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
CN104870009B (en) 2012-12-21 2021-05-18 赛诺菲 Functionalized exendin-4 derivatives
TW201609795A (en) 2013-12-13 2016-03-16 賽諾菲公司 EXENDIN-4 peptide analogues as dual GLP-1/GIP receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
TW201625669A (en) 2014-04-07 2016-07-16 賽諾菲公司 Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
TW201625670A (en) 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
TW201625668A (en) 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN104888198A (en) * 2015-04-21 2015-09-09 徐志强 New application of calcitonin to preparing medicines for delaying brain aging
AR105319A1 (en) 2015-06-05 2017-09-27 Sanofi Sa PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
TW201706291A (en) 2015-07-10 2017-02-16 賽諾菲公司 New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
US10883132B2 (en) * 2018-03-09 2021-01-05 Enzypep B.V. Chemo-enzymatic synthesis of Semaglutide, Liraglutide and GLP-1
CN115896029A (en) * 2023-01-09 2023-04-04 中国人民解放军军事科学院军事医学研究院 Application of calcitonin gene-related peptide in treating Parkinson's disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012099A1 (en) * 1998-09-02 2000-03-09 The Regents Of The University Of California Promoters of neural regeneration
WO2004045592A2 (en) * 2002-11-20 2004-06-03 Neuronova Ab Compounds and methods for increasing neurogenesis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012099A1 (en) * 1998-09-02 2000-03-09 The Regents Of The University Of California Promoters of neural regeneration
WO2004045592A2 (en) * 2002-11-20 2004-06-03 Neuronova Ab Compounds and methods for increasing neurogenesis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
PERRY TRACYANN ET AL: "A novel neurotrophic property of glucagon-like peptide 1: A promoter of nerve growth factor-mediated differentiation in PC12 cells", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 300, no. 3, March 2002 (2002-03-01), pages 958 - 966, XP002402955, ISSN: 0022-3565 *
PERRY TRACYANN ET AL: "Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 302, no. 3, September 2002 (2002-09-01), pages 881 - 888, XP002402954, ISSN: 0022-3565 *
RYDEL R E ET AL: "CAMP ANALOGS PROMOTE SURVIVAL AND NEURITE OUTGROWTH IN CULTURES OF RAT SYMPATHETIC AND SENSORY NEURONS INDEPENDENTLY OF NERVE GROWTH FACTOR", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 85, February 1988 (1988-02-01), pages 1257 - 1261, XP002923654, ISSN: 0027-8424 *
THORNE R G ET AL: "DELIVERY OF NEUROTROPHIC FACTORS TO THE CENTRAL NERVOUS SYSTEM - PHARMACOKINETIC CONSIDERATIONS", CLINICAL PHARMACOKINETICS, LEA & FEBIGER, PHILADELPHIA, PA, US, vol. 40, no. 12, 2001, pages 907 - 946, XP009071751 *

Also Published As

Publication number Publication date
CA2546843A1 (en) 2005-09-09
WO2005081619A2 (en) 2005-09-09
CA2546843C (en) 2015-01-06
EP1750752A2 (en) 2007-02-14

Similar Documents

Publication Publication Date Title
WO2005081619A3 (en) Compounds and methods for increasing neurogenesis
WO2005103041A3 (en) Treatment of cns disorders using cns target modulators
WO2004045592A3 (en) Compounds and methods for increasing neurogenesis
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
NO20043237L (en) Dihydrobenzodiazepine-2-derivatives for the treatment of neurological disorders
AU2002327378A1 (en) Treatment of neuropsychiatric disorders by near-diaphragmatic nerve stimulation
WO2004014352A3 (en) Methods for treating carbonic anhydrase mediated disorders
WO2004106492A3 (en) Bicyclicpyrimidones and their use to treat diseases
AU2003286567A1 (en) Methods for the treatment of skin disorders
WO2001060806A3 (en) Substituted arylpyrazines
WO2005037232A3 (en) Methods and compositions for modulating adipocyte function
AU2001263447A1 (en) Stimulation method for the sphenopalatine ganglia, sphenopalatine nerve, or vidian nerve for treatment of medical conditions
EP2286839A3 (en) Treatment of obesity and related diseases
TW200607513A (en) Certain chemical entities, compositions, and methods
WO2005039504A3 (en) Compounds and methods for treating toll-like receptor 2-related diseases and conditions
WO2007134136A3 (en) Neurogenesis by modulating angiotensin
EE200300559A (en) Use of Osteopontin for the treatment and / or prevention of neurological disorders
AU2002356525A1 (en) Substituted amines for the treatment of neurological disorders
WO2006135694A3 (en) Uii-modulating compounds and their use
EP1802321A4 (en) Compositions and methods for modulating pgc-1-alpha to treat neurological diseases and disorders
WO2004073607A3 (en) Use of steroids to treat ocular disorders
ZA200609220B (en) Method of treating dry eye disorders and uveitis
WO2001021647A3 (en) Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases
WO2004009064A8 (en) Use of neurotoxic substances for the production of a means for the treatment of joint pain and method for application of said means
WO2004091646A3 (en) Use of slurp-1 for treating diseases related to acetylcholine receptors dysfunction

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2546843

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2004821493

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004821493

Country of ref document: EP